BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Intellia Therapeutics Inc. (NASDAQ:NTLA) hired David Lebwohl as EVP and CMO. He was CMO of Semma Therapeutics Inc....
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

...transplantation of insulin-producing β beta cells (see “Islets of Hope” ). Leading the approach is Semma Therapeutics Inc....
BioCentury | Oct 11, 2019
Finance

Beyond diabetes: T1D Fund’s new remit broadens venture base

...the IPO of Provention Bio Inc. (NASDAQ:PRVB) and the sale of cell therapy play Semma Therapeutics Inc....
BioCentury | Sep 30, 2019
Company News

Vertex seeks small molecules for RNA in deal with Ribometrix

...well as new disease indications, such as diabetes and muscular dystrophies via deals to acquire Semma Therapeutics Inc....
...shock protein 90; HTT - Huntingtin Allison Johnson, Senior Writer Ribometrix Inc. Vertex Pharmaceuticals Inc. Arrakis Therapeutics Inc. Expansion Therapeutics Inc. Semma Therapeutics Inc. Exonics...
BioCentury | Sep 27, 2019
Preclinical News

Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

...mesenchymal stem cells, which supplants encapsulation and immunosuppressants for protecting the islets from immune cells. Semma Therapeutics Inc....
BioCentury | Sep 3, 2019
Company News

Via $950M Semma takeout, Vertex moves into diabetes and cell therapy

...its stem cell-derived islet program. The acquisition marks Vertex's entry into diabetes and cell therapy. Semma Therapeutics Inc....
...R&D Efficiency" ). Vertex expects the Semma acquisition to close next quarter. Elizabeth S. Eaton, Staff Writer Semma Therapeutics Inc. Vertex...
BioCentury | Jul 2, 2019
Preclinical News

July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

...Semma to bring stem cell-derived islet therapies for diabetes to clinic in 2020 Semma Therapeutics Inc. (Cambridge, Mass...
...Huntingtin Sandi Wong, Staff Writer Hebrew University of Jerusalem Massachusetts Institute of Technology Orion Biotechnology Canada Ltd. Sangamo Therapeutics Inc. Semma Therapeutics Inc. Takeda...
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...member. Mead was president and CEO of Beaver-Visitec International Inc. (Waltham, Mass.). Regenerative medicine company Semma Therapeutics Inc....
...Chris Lieu, Staff Writers Alnylam Pharmaceuticals Inc. ArcherDx Audentes Therapeutics Inc. Black Diamond Therapeutics Inc. eTheRNA immunotherapies N.V. Gilead HeartFlow Inc. Protagonist Therapeutics Inc. Semma Therapeutics Inc. Sirnaomics...
BioCentury | Dec 18, 2018
Company News

Management tracks: AbbVie, Semma, Ziopharm

...administration. All four executives report to Chairman and CEO Richard A. Gonzalez. Cell therapy company Semma Therapeutics Inc....
BioCentury | Jun 1, 2018
Finance

Distribution to innovation

...U.S. dollar fund has made six investments, including Ansun BioPharma Inc. and cell therapy company Semma Therapeutics Inc....
Items per page:
1 - 10 of 29
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Intellia Therapeutics Inc. (NASDAQ:NTLA) hired David Lebwohl as EVP and CMO. He was CMO of Semma Therapeutics Inc....
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

...transplantation of insulin-producing β beta cells (see “Islets of Hope” ). Leading the approach is Semma Therapeutics Inc....
BioCentury | Oct 11, 2019
Finance

Beyond diabetes: T1D Fund’s new remit broadens venture base

...the IPO of Provention Bio Inc. (NASDAQ:PRVB) and the sale of cell therapy play Semma Therapeutics Inc....
BioCentury | Sep 30, 2019
Company News

Vertex seeks small molecules for RNA in deal with Ribometrix

...well as new disease indications, such as diabetes and muscular dystrophies via deals to acquire Semma Therapeutics Inc....
...shock protein 90; HTT - Huntingtin Allison Johnson, Senior Writer Ribometrix Inc. Vertex Pharmaceuticals Inc. Arrakis Therapeutics Inc. Expansion Therapeutics Inc. Semma Therapeutics Inc. Exonics...
BioCentury | Sep 27, 2019
Preclinical News

Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

...mesenchymal stem cells, which supplants encapsulation and immunosuppressants for protecting the islets from immune cells. Semma Therapeutics Inc....
BioCentury | Sep 3, 2019
Company News

Via $950M Semma takeout, Vertex moves into diabetes and cell therapy

...its stem cell-derived islet program. The acquisition marks Vertex's entry into diabetes and cell therapy. Semma Therapeutics Inc....
...R&D Efficiency" ). Vertex expects the Semma acquisition to close next quarter. Elizabeth S. Eaton, Staff Writer Semma Therapeutics Inc. Vertex...
BioCentury | Jul 2, 2019
Preclinical News

July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

...Semma to bring stem cell-derived islet therapies for diabetes to clinic in 2020 Semma Therapeutics Inc. (Cambridge, Mass...
...Huntingtin Sandi Wong, Staff Writer Hebrew University of Jerusalem Massachusetts Institute of Technology Orion Biotechnology Canada Ltd. Sangamo Therapeutics Inc. Semma Therapeutics Inc. Takeda...
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...member. Mead was president and CEO of Beaver-Visitec International Inc. (Waltham, Mass.). Regenerative medicine company Semma Therapeutics Inc....
...Chris Lieu, Staff Writers Alnylam Pharmaceuticals Inc. ArcherDx Audentes Therapeutics Inc. Black Diamond Therapeutics Inc. eTheRNA immunotherapies N.V. Gilead HeartFlow Inc. Protagonist Therapeutics Inc. Semma Therapeutics Inc. Sirnaomics...
BioCentury | Dec 18, 2018
Company News

Management tracks: AbbVie, Semma, Ziopharm

...administration. All four executives report to Chairman and CEO Richard A. Gonzalez. Cell therapy company Semma Therapeutics Inc....
BioCentury | Jun 1, 2018
Finance

Distribution to innovation

...U.S. dollar fund has made six investments, including Ansun BioPharma Inc. and cell therapy company Semma Therapeutics Inc....
Items per page:
1 - 10 of 29